FDA Okays Cubist Pharmaceuticals’ (CBST) Drug For Antibiotic-Resistant Bacteria

December 20, 2014 2:19 PM

5 0

Cubist’s experimental antibiotic Zerbaxa has been approved by the FDA for the treatment of complicated urinary tract and intra-abdominal infections

The US Food and Drug Administration (FDA) on Friday approved Cubist Pharmaceuticals, Inc.’s (NASDAQ:CBST) experimental antibiotic Zerbaxa for the treatment of complicated urinary tract infection (cUTI) and complicated intra-abdominal infection (cIAI), marking the second antibiotic approval for the c...

Read more

To category page

Loading...